GRCE — Grace Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1444192 ·
Last close
$1.72
Market Cap
$36.18M
52W High
$5.18
52W Low
$1.64
ADV30
105,779
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -2,292,000 | -2,131,000 | 57,698,000 | 21,311,000 | 2,218,000 |
| Jun 2026 | 0 | — | -2,384,000 | -15,790,000 | 50,073,000 | 13,756,000 | 1,862,000 |
| Mar 2026 | 0 | — | -3,010,000 | -1,178,000 | 66,654,000 | 16,977,000 | 2,758,000 |
| Dec 2025 | 0 | — | -2,449,000 | -2,315,000 | 68,488,000 | 18,672,000 | 3,596,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,930,000
Investing CF
$0
Financing CF
$13,379,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.22
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-246,401,000
Inventory
—
Receivables
$20,000
ST Investments
—
EBIT TTM
$-10,135,000
Pretax Income TTM
$-23,122,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -11,077,000 | -7,793,000 | 66,654,000 | 2,758,000 | 63,896,000 | -8,869,000 |
| Mar 2025 | 0 | -16,679,000 | -9,568,000 | 71,993,000 | 5,383,000 | 66,610,000 | -14,904,000 |
| Mar 2024 | 0 | -11,367,000 | -12,853,000 | 73,300,000 | 11,557,000 | 61,743,000 | -12,333,000 |
| Mar 2023 | 0 | -18,247,000 | -42,429,000 | 79,123,000 | 11,168,000 | 67,955,000 | -15,913,000 |
| Mar 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$621,000
NetIncome TTM
$-20,221,000
OpCashFlow TTM
—
Assets (Latest)
$50,073,000
Forward EPS
$-0.42
Max Pain — expiry 2027-05-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.73 · call volume: 1 · put volume: 362
Expected Move to 2027-05-21:
±$1.17
(67.92%) —
implied range
$0.56 –
$2.91
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SER | Serina Therapeutics, Inc. | $36.27M | $1.37 | — |
| CNTB | Connect Biopharma Holdings Ltd | $36.45M | $0.58 | — |
| VERU | VERU INC. | $36.49M | $2.14 | — |
| BMEA | Biomea Fusion, Inc. | $35.47M | $0.49 | — |
| OSTX | OS Therapies Inc | $34.86M | $0.74 | — |
News headlines (Yahoo Finance, 1h cache)
Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business Update
2026-11-12 13:00 · Yahoo
Grace: Fiscal Q2 Earnings Snapshot
2026-11-12 12:58 · Yahoo
Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026
2026-11-05 13:00 · Yahoo
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference
2026-09-03 12:00 · Yahoo
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
2026-08-13 12:00 · Yahoo
Grace Therapeutics Announces $10 Million Private Placement
2026-08-05 01:00 · Yahoo
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
2026-07-28 11:00 · Yahoo
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
2026-06-18 12:00 · Yahoo
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
2026-04-23 17:13 · Yahoo
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
2026-04-14 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.